New
GLP2 TRZ - 30mg
0 Reviews
Published By In Lab Peptides
$209.00 (USD)
- Location: United States
- Status: In stock
Details
Three Receptors, One Molecule: The Science of Triple Agonism
Retatrutide represents the next generation of incretin-based research compounds. Unlike dual-agonists such as Tirzepatide, it targets three key receptors simultaneously: GLP-1, GIP, and Glucagon. This triple-agonist mechanism has been extensively documented in peer-reviewed literature for its interaction with metabolic signaling pathways and receptor cross-talk.
Activates GLP-1, GIP, and Glucagon receptors simultaneously
First compound designed with this triple-agonist mechanism
Extended half-life suitable for weekly research protocols
Well-documented in peer-reviewed scientific journals
Stable compound suitable for in-vitro research protocols
Related Products
